Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus usual-dose hyoscine during ERCP
IRCT20180421039368N1Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of hyoscine butylbromide in gallbladder disease and biliary disease (2 arms), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoints: Minimum effective dose for anti-motility response, Duration of anti-motility response and 1 more. Started Jun 2018; status: completed.
02
Drugs
hyoscine butylbromide
03
Conditions
gallbladder diseasebiliary disease
Beyond the preview
Go deeper on IRCT20180421039368N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180421039368N1.